The Enterprise Value as of July 2024 (TTM) for Madrigal Pharmaceuticals, Inc. (MDGL) is 5.56B

According to Madrigal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.56B. This represents a change of 37.19% compared to the average of 4.05B of the last 4 quarters.

Madrigal Pharmaceuticals, Inc. (MDGL) Historical Enterprise Value (quarterly & annually)

How has MDGL Enterprise Value performed in the past?

The mean historical Enterprise Value of Madrigal Pharmaceuticals, Inc. over the last ten years is 1.58B. The current 5.56B Enterprise Value has changed 35.14% with respect to the historical average. Over the past ten years (40 quarters), MDGL's Enterprise Value was at its highest in in the December 2022 quarter at 4.72B. The Enterprise Value was at its lowest in in the March 2016 quarter at -39003272.80.

Madrigal Pharmaceuticals, Inc. (MDGL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Madrigal Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Madrigal Pharmaceuticals, Inc. (MDGL) Average Enterprise Value

How has MDGL Enterprise Value performed in the past?

The current Enterprise Value of Madrigal Pharmaceuticals, Inc. (MDGL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Madrigal Pharmaceuticals, Inc. (MDGL) Enterprise Value vs. Peers

How is MDGL’s Enterprise Value compared to its peers?

Madrigal Pharmaceuticals, Inc.’s Enterprise Value is greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than TG Therapeutics, Inc. (3.21B), greater than Terns Pharmaceuticals, Inc. (518.07M), greater than Hepion Pharmaceuticals, Inc. (-8319926.00), less than Viking Therapeutics, Inc. (7.23B), less than Sarepta Therapeutics, Inc. (14.59B), greater than PTC Therapeutics, Inc. (2.49B), greater than Day One Biopharmaceuticals, Inc. (1.13B), greater than X4 Pharmaceuticals, Inc. (142.54M), greater than Inozyme Pharma, Inc. (386.63M), greater than Acumen Pharmaceuticals, Inc. (192.73M), greater than Mereo BioPharma Group plc (540.18M), greater than 89bio, Inc. (718.79M), greater than Pliant Therapeutics, Inc. (746.91M), greater than Arcellx, Inc. (3.38B), greater than Stoke Therapeutics, Inc. (654.39M), less than Krystal Biotech, Inc. (5.75B), greater than Iovance Biotherapeutics, Inc. (2.54B),

Build a custom stock screener for Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Madrigal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Madrigal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.